Search Results - "Pro, Barbara"

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study by PRO, Barbara, ADVANI, Ranjana, YIN YANG, SIEVERS, Eric L, KENNEDY, Dana A, SHUSTOV, Andrei, BRICE, Pauline, BARTLETT, Nancy L, ROSENBLATT, Joseph D, ILLIDGE, Tim, MATOUS, Jeffrey, RAMCHANDREN, Radhakrishnan, FANALE, Michelle, CONNORS, Joseph M

“…Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell lymphoma characterized by the uniform expression of CD30. The antibody-drug…”
Get full text

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy by COIFFIER, Bertrand, PRO, Barbara, PINTER-BROWN, Lauren, PADMANABHAN, Swaminathan, SHUSTOV, Andrei, NICHOLS, Jean, CARROLL, Susan, BALSER, John, BALSER, Barbara, HORWITZ, Steven, PRINCE, H. Miles, FOSS, Francine, SOKOL, Lubomir, GREENWOOD, Matthew, CABALLERO, Dolores, BORCHMANN, Peter, MORSCHHAUSER, Franck, WILHELM, Martin

“…Romidepsin is a structurally unique, potent class 1 selective histone deacetylase inhibitor. The primary objective of this international, pivotal, single-arm,…”
Get full text

Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E) by Park, Joonhee, Yang, Jingyi, Wenzel, Alexander T., Ramachandran, Akshaya, Lee, Wung J., Daniels, Jay C., Kim, Juhyun, Martinez-Escala, Estela, Amankulor, Nduka, Pro, Barbara, Guitart, Joan, Mendillo, Marc L., Savas, Jeffrey N., Boggon, Titus J., Choi, Jaehyuk

“…Cutaneous T-cell lymphoma (CTCL) is an incurable non-Hodgkin lymphoma of the skin-homing T cell. In early-stage disease, lesions are limited to the skin, but…”
Get full text

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study by O'CONNOR, Owen A, PRO, Barbara, JACOBSEN, Eric, LUIGI ZINZANI, Pier, FURMAN, Richard, GOY, Andre, HAIOUN, Corinne, CRUMP, Michael, ZAIN, Jasmine M, HSI, Eric, BOYD, Adam, HORWITZ, Steven, PINTER-BROWN, Lauren, BARTLETT, Nancy, POPPLEWELL, Leslie, COIFFIER, Bertrand, JO LECHOWICZ, Mary, SAVAGE, Kerry J, SHUSTOV, Andrei R, GISSELBRECHT, Christian

“…Peripheral T-cell lymphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's lymphoma with no accepted standard of care. This study evaluated the efficacy…”
Get full text

Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project by FEDERICO, Massimo, BELLEI, Monica, CORTELAZZO, Sergio, MARTINELLI, Giovanni, MARTELLI, Maurizio, RIGACCI, Luigi, ARCAINI, Luca, DI RAIMONDO, Francesco, MERLI, Francesco, SABATTINI, Elena, MCLAUGHLIN, Peter, SOLAL-CELIGNY, Philippe, MARCHESELLI, Luigi, LUMINARI, Stefano, LOPEZ-GUILLERMO, Armando, VITOLO, Umberto, PRO, Barbara, PILERI, Stefano, PULSONI, Alessandro, SOUBEYRAN, Pierre

“…The aim of the F2 study was to verify whether a prospective collection of data would enable the development of a more accurate prognostic index for follicular…”
Get full text

Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas by Daniels, Jay, Doukas, Peter G., Escala, Maria E. Martinez, Ringbloom, Kimberly G., Shih, David J. H., Yang, Jingyi, Tegtmeyer, Kyle, Park, Joonhee, Thomas, Jane J., Selli, Mehmet E., Altunbulakli, Can, Gowthaman, Ragul, Mo, Samuel H., Jothishankar, Balaji, Pease, David R., Pro, Barbara, Abdulla, Farah R., Shea, Christopher, Sahni, Nidhi, Gru, Alejandro A., Pierce, Brian G., Louissaint, Abner, Guitart, Joan, Choi, Jaehyuk

“…Primary cutaneous γδ T cell lymphomas (PCGDTLs) represent a heterogeneous group of uncommon but aggressive cancers. Herein, we perform genome-wide DNA, RNA,…”
Get full text

Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium by SMITH, Sonali M, VAN BESIEN, Koen, AUSTIN DOYLE, L, VOKES, Everett E, PRO, Barbara, KARRISON, Theodore, DANCEY, Janet, MCLAUGHLIN, Peter, YOUNES, Anas, SMITH, Scott, STIFF, Patrick, LESTER, Eric, MODI, Sanjiv

“…Despite high initial remission rates, most lymphomas relapse and require further therapy. The mammalian target of rapamycin (mTOR) pathway is a validated…”
Get full text

Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial by Bryan, Locke J., Casulo, Carla, Allen, Pamela, Smith, Scott E., Savas, Hatice, Karmali, Reem, Pro, Barbara, O'Shea, Kaitlyn, Chmiel, Joan, Palmer, Brett Alan, Mehta, Jayesh, Gordon, Leo I., Winter, Jane N.

“…▪ Introduction: Approximately 30-35% of patients with classic Hodgkin Lymphoma will prove refractory to frontline therapy or relapse subsequently. Traditional…”
Get full text

Watchful Waiting in Low–Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database by SOLAL-CELIGNY, Philippe, BELLEI, Monica, DECONINCK, Eric, MILPIED, Noel, GORDON, Leo I, FEDERICO, Massimo, MARCHESELLI, Luigi, PESCE, Emanuela Anna, PILERI, Stefano, MCLAUGHLIN, Peter, LUMINARI, Stefano, PRO, Barbara, MONTOTO, Silvia, FERRERI, Andrés J. M

“…Patients with follicular lymphoma (FL) registered in the F2-study and initially managed without treatment were analyzed to describe the presentation and…”
Get full text

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma by Tam, Constantine S., Bassett, Roland, Ledesma, Celina, Korbling, Martin, Alousi, Amin, Hosing, Chitra, Kebraei, Partow, Harrell, Robyn, Rondon, Gabriela, Giralt, Sergio A., Anderlini, Paolo, Popat, Uday, Pro, Barbara, Samuels, Barry, Hagemeister, Frederick, Medeiros, L. Jeffrey, Champlin, Richard E., Khouri, Issa F.

“…In this study, we analyzed the long-term outcome of a risk-adapted transplantation strategy for mantle cell lymphoma in 121 patients enrolled in sequential…”
Get full text

Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma by GOY, Andre, YOUNES, Anas, BROGLIO, Kristine, SAMUELS, Barry, GILLES, Frederic, SARRIS, Andreas H, HART, Susan, TREHU, Elizabeth, SCHENKEIN, David, CABANILLAS, Fernando, RODRIGUEZ, Alma M, MCLAUGHLIN, Peter, PRO, Barbara, ROMAGUERA, Jorge E, HAGEMEISTER, Frederick, FAYAD, Luis, DANG, Nam H, SAMANIEGO, Felipe, WANG, Michael

“…Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Patients were stratified, based on…”
Get full text

Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial by Foss, Francine, Horwitz, Steven, Pro, Barbara, Prince, H Miles, Sokol, Lubomir, Balser, Barbara, Wolfson, Julie, Coiffier, Bertrand

“…Achievement of durable responses in patients with relapsed/refractory peripheral T cell lymphoma (PTCL) is challenging with current therapies, and there are…”
Get full text

High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine by ROMAGUERA, Jorge E, FAYAD, Luis, SARRIS, Andreas H, DANG, Nam H, WANG, Michael, BEASLEY, Virginia, MEDEIROS, L. Jeffrey, KATZ, Ruth L, GAGNEJA, Harish, SAMUELS, Barry I, SMITH, Terry L, CABANILLAS, Fernando F, RODRIGUEZ, Maria A, BROGHO, Kristine R, HAGEMEISTER, Frederick B, PRO, Barbara, MCLAUGHHN, Peter, YOUNES, Anas, SAMANIEGO, Felipe, GOY, Andre

“…To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients…”
Get full text

Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study) by Messina, Carlo, Ferreri, Andrés J. M., Govi, Silvia, Bruno‐Ventre, Marta, Gracia Medina, Elías A., Porter, David, Radford, John, Heo, Dae S., Park, Hee Y., Pro, Barbara, Jayamohan, Jayasingham, Visco, Carlo, Scarfò, Lydia, Zucca, Emanuele, Gospodarowicz, Mary, Christie, David

“…Summary ‘Multifocal bone lymphoma’ or ‘polyostotic lymphoma’ is a neoplasm with exclusive multifocal involvement of the skeleton, without affecting lymph nodes…”
Get full text

Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma by WANG, Michael, OKI, Yasuhiro, SAMUELS, Barry I, LOYER, Evelyne M, YUAN JI, YOUNES, Anas, PRO, Barbara, ENRIQUE ROMAGUERA, Jorge, ALMA RODRIGUEZ, Maria, SAMANIEGO, Felipe, MCLAUGHLIN, Peter, HAGEMEISTER, Frederick, NEELAPU, Sattva, COPELAND, Amanda

“…This phase II trial evaluated the safety and efficacy of yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma…”
Get full text

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2 by Savage, Kerry J., Horwitz, Steven M., Advani, Ranjana, Christensen, Jacob Haaber, Domingo-Domenech, Eva, Rossi, Giuseppe, Morschhauser, Franck, Alpdogan, Onder, Suh, Cheolwon, Tobinai, Kensei, Shustov, Andrei, Trneny, Marek, Yuen, Sam, Zinzani, Pier Luigi, Trümper, Lorenz, Ilidge, Tim, O’Connor, Owen A., Pro, Barbara, Miao, Harry, Bunn, Veronica, Fenton, Keenan, Fanale, Michelle, Puhlmann, Markus, Iyer, Swaminathan

“…•Consolidative SCT should be considered in patients with CD30+PTCL in a CR following frontline treatment with A+CHP.•Further studies are needed to establish…”
Get full text

Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center by QI LIU, FAYAD, Luis, YOUNES, Anas, PRO, Barbara, LEE, Ming-Sheng, AYALA, Ana, MCLAUGHLIN, Peter, CABANILLAS, Fernando, HAGEMEISTER, Fredrick B, AYERS, Gregory D, HESS, Mark, ROMAGUERA, Jorge, RODRIGUEZ, M. Alma, TSIMBERIDOU, Apostolia M, VERSTOVSEK, Srdan

“…Advanced-stage follicular lymphoma is considered incurable. The pace of improvements in treatment has been slow. This article analyzes five sequential cohorts…”
Get full text

Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma by Karmali, Reem, St‐Pierre, Frederique, Ma, Shuo, Foster, Kelly D., Kaplan, Jason, Mi, Xinlei, Pro, Barbara, Winter, Jane N., Gordon, Leo I.

“…Background: TAK‐659, a novel oral SYK inhibitor, has demonstrated efficacy in heavily pretreated diffuse large B‐cell lymphoma (DLBCL). We report results of a…”
Get full text

Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms by RAVANDI, Farhad, ARIBI, Ahmed, KONTOYIANNIS, Dimitrios, VERSTOVSEK, Srdan, PRO, Barbara, FAYAD, Luis, KEATING, Michael, KANTARJIAN, Hagop, O'BRIEN, Susan, FADERL, Stefan, JONES, Dan, FERRAJOLI, Alessandra, XUELIN HUANG, YORK, Sergernne, PIERCE, Sherry, WIERDA, William

“…To examine the efficacy and safety of the combination of alemtuzumab and pentostatin in patients with T-cell neoplasms. We treated 24 patients with a variety…”
Get full text

Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature by Soriano, Andres O., Thompson, Michael A., Admirand, Joan H., Fayad, Luis E., Rodriguez, Alma M., Romaguera, Jorge E., Hagemeister, Fredrick B., Pro, Barbara

“…Follicular dendritic cell sarcomas (FDCS) are grouped with the histiocytic and dendritic cell neoplasms. The natural history and response to different…”
Get full text